Pharmaceutical and biotechnology major Wockhardt has received US Food and Drug Administration (USFDA) approval for marketing a generic version of 200mg tablets containing Entacapone, which is used in the treatment of Parkinson’s disease.
Entacapone tablet is the generic name for the brand Comtan, owned by Orion Corporation and marketed in the US by Novartis. Wockhardt will launch the product on September 30, 2012, with 180-days of exclusivity.
The incidence of Parkinson’s disease is increasing worldwide. According to IMS Health, the total market for this product in the US is about $98 million.
Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s , the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.
